Evidence map›Paper›PMID 35032330›Full record

ReviewLetters in applied microbiology2022

Antifungal lock therapy: an eternal promise or an effective alternative therapeutic approach?

R Kovács, L Majoros

Open access · hybridAbstract readReview
In one paragraph

Review in Letters in applied microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. StudyingPharmaceuticals (Basel, Switzerland) · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Consensus paper onTurkish journal of medical sciences · 2025
    Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

R KovácsDepartment of Medical Microbiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.ORCID https://orcid.org/0000-0003-3946-2424
L MajorosDepartment of Medical Microbiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
University of Debrecen · HU

Funding

Hungarian Academy of SciencesHungarian National Research, Development and Innovation Office NKFIH FK138462
6 · The paper itself

Abstract

Each year, millions of central venous catheter insertions are performed in intensive care units worldwide. The usage of these indwelling devices is associated with a high risk of bacterial and fungal colonization, leading to the development of microbial consortia, namely biofilms. These sessile structures provide fungal cells with resistance to the majority of antifungals, environmental stress and host immune responses. Based on different guidelines, colonized/infected catheters should be removed and changed immediately in the case of Candida-related central line infections. However, catheter replacement is not feasible for all patient populations. An alternative therapeutic approach may be antifungal lock therapy, which has received high interest, especially in the last decade. This review summarizes the published Candida-related in vitro, in vivo data and case studies in terms of antifungal lock therapy. The number of clinical studies remains limited and further studies are needed for safe implementation of the antifungal lock therapy into clinical practice.

Indexed as

Antifungal AgentsCandidaBiofilmsHumansAntifungal Agentsantifungal lock therapybiofilmCandidaCandida auriscandidaemiacatheter-associated infection

Identifiers

PMID35032330
PMCPMC9306927
OpenAlexW4205401735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.